Increases in circulating adiponectin have been linked to the ability of TZDs to limit the progression of NAFLD to NASH (Gastaldelli et al, 2010; Warshauer et al, 2015; Cusi et al, 2016; Li et al, 2019). Here, ADIPOQ is linked to metabolic dysfunction-associated steatohepatitis.